Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3
A recent clinical trial in African children demonstrated the potential utility of merozoite surface protein (MSP)-3 as a vaccine against Plasmodium falciparum malaria. The present study evaluated the use of Plasmodium vivax MSP-3 (PvMSP-3) as a target antigen in vaccine formulations against malaria...
Prif Awduron: | Bitencourt, A, Vicentin, E, Jimenez, M, Ricci, R, Leite, J, Costa, F, Ferreira, L, Russell, B, Nosten, F, Rénia, L, Galinski, MR, Barnwell, J, Rodrigues, M, Soares, I |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
Public Library of Science
2013
|
Eitemau Tebyg
-
Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3.
gan: Amanda R Bitencourt, et al.
Cyhoeddwyd: (2013-01-01) -
<it>Plasmodium vivax</it>: who cares?
gan: Barnwell John W, et al.
Cyhoeddwyd: (2008-12-01) -
Plasmodium vivax merozoite surface protein-3 (PvMSP3): expression of an 11 member multigene family in blood-stage parasites.
gan: Jianlin Jiang, et al.
Cyhoeddwyd: (2013-01-01) -
Plasmodium vivax merozoite surface protein 1 paralog as a mediator of parasite adherence to reticulocytes
gan: Han, J, et al.
Cyhoeddwyd: (2018) -
Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast.
gan: Vicentin, E, et al.
Cyhoeddwyd: (2014)